

**PRESS RELEASE**

15 August 2024 08:30:00 CEST



## **Lipum to participate in the following upcoming events and meetings**

**Lipum AB (publ), a clinical stage biopharmaceutical company developing the drug candidate SOL-116 focused on chronic inflammatory diseases, today announced its participation in the following upcoming events during the autumn of 2024.**

**NLSDays** | 18-19 September | Malmö

**BioEurope** | 4-6 November | Stockholm

**Redeye Autoinflammatory day** | 20 November | Stockholm

**BioStockSummit** | 20-21 November | Lund

"These meetings provide a good opportunity for us to present and discuss our progress and results from our first clinical phase 1 study, to share our ongoing plans as well as presenting key milestones and triggers with investors and partners" says CEO Ola Sandborgh.

### **Contacts**

Ola Sandborgh, CEO

[ola.sandborgh@lipum.se](mailto:ola.sandborgh@lipum.se)

+46 72 218 80 21

Web: [www.lipum.se](http://www.lipum.se)

### **About Us**

Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical stage supported by solid data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum's unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

### **Attachments**

[Lipum to participate in the following upcoming events and meetings](#)